Poseida Therapeutics Presents Novel BCMA-Specific CAR-T Therapy at CAR-TCR Summit

Poseida Therapeutics Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving cell therapies, today presented preclinical data on P-BCMA-101, the company’s BCMA-specific CAR-T drug candidate for the treatment of multiple myeloma, at the CAR-TCR Summit on T Cell Immunotherapies in Boston.

Read the full press releaseCompany website